The synergistic effects of PRDX5 and Nrf2 on lung cancer progression and drug resistance under oxidative stress in the zebrafish models

Previous studies have shown that PRDX5 and Nrf2 are antioxidant proteins related to abnormal reactive oxidative species (ROS). PRDX5 and Nrf2 play a critical role in the progression of inflammations and tumors. The combination of PRDX5 and Nrf2 was examined by Co-immunoprecipitation, western blotting and Immunohistochemistry. H2O2 was applied to affect the production of ROS and induced multi-resistant protein 1 (MRP1) expression in NSCLC cells. The zebrafish models mainly investigated the synergistic effects of PRDX5 and Nrf2 on lung cancer drug resistance under oxidative stress. We showed that PRDX5 and Nrf2 form a complex and significantly increase the NSCLC tissues compared to adjacent tissues. The oxidative stress improved the combination of PRDX5 and Nrf2. We demonstrated that the synergy between PRDX5 and Nrf2 is positively related to the proliferation and drug resistance of NSCLC cells in the zebrafish models. In conclusion, our data indicated that PRDX5 could bind to Nrf2 and has a synergistic effect with Nrf2. Meanwhile, in the zebrafish models, PRDX5 and Nrf2 have significant regulatory impacts on lung cancer progression and drug resistance activities under oxidative stress.

[1]  J. Fletcher,et al.  Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[2]  Siyi Qian,et al.  Zebrafish xenograft model for studying mechanism and treatment of non-small cell lung cancer brain metastasis , 2021, Journal of Experimental & Clinical Cancer Research.

[3]  Zhe-Sheng Chen,et al.  ATP‐binding cassette (ABC) transporters in cancer: A review of recent updates , 2021, Journal of evidence-based medicine.

[4]  Lizong Shen,et al.  Prediction of Sensitivity and Efficacy of Clinical Chemotherapy Using Larval Zebrafish Patient-Derived Xenografts of Gastric Cancer , 2021, Frontiers in Cell and Developmental Biology.

[5]  Jun Wang,et al.  Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment , 2020, Frontiers in Immunology.

[6]  J. Kopecka,et al.  MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor , 2020, International journal of molecular sciences.

[7]  Ben Li,et al.  PRDX5 as a novel binding partner in Nrf2-mediated NSCLC progression under oxidative stress , 2020, Aging.

[8]  M. Kumar,et al.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission , 2019, The Lancet Gastroenterology & Hepatology.

[9]  M. Smid,et al.  Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression , 2019, Breast Cancer Research.

[10]  Dong-Seok Lee,et al.  Interplay Between Mitochondrial Peroxiredoxins and ROS in Cancer Development and Progression , 2019, International journal of molecular sciences.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  W. Gu,et al.  NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression. , 2017, Molecular cell.

[13]  R. Taneja,et al.  Stressing the (Epi)Genome: Dealing with Reactive Oxygen Species in Cancer. , 2017, Antioxidants & redox signaling.

[14]  T. Cotter,et al.  ROS signalling in the biology of cancer. , 2017, Seminars in cell & developmental biology.

[15]  D. Tuveson,et al.  ROS in Cancer: The Burning Question. , 2017, Trends in molecular medicine.

[16]  D. Heymann,et al.  Zebrafish xenograft models of cancer and metastasis for drug discovery , 2017, Expert opinion on drug discovery.

[17]  Yuan Zhang,et al.  Quantitative proteomic analysis of gastric cancer tissue reveals novel proteins in platelet-derived growth factor B signaling pathway , 2017, Oncotarget.

[18]  Xupeng Bai,et al.  Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters , 2016, Drug metabolism reviews.

[19]  K. Węglarczyk,et al.  Nrf2-heme oxygenase-1 axis in mucoepidermoid carcinoma of the lung: Antitumoral effects associated with down-regulation of matrix metalloproteinases. , 2015, Free radical biology & medicine.

[20]  Adam Hurlstone,et al.  Zebrafish: A New Companion for Translational Research in Oncology , 2015, Clinical Cancer Research.

[21]  Y. Soini,et al.  Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas , 2014, Histopathology.

[22]  Akhileshwar Namani,et al.  Modulation of NRF2 signaling pathway by nuclear receptors: implications for cancer. , 2014, Biochimica et biophysica acta.

[23]  T. Shimosegawa,et al.  Myeloid Lineage–Specific Deletion of Antioxidant System Enhances Tumor Metastasis , 2014, Cancer Prevention Research.

[24]  S. Chuang,et al.  Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism. , 2013, Free radical biology & medicine.

[25]  Junchao Cai,et al.  miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. , 2013, Cancer research.

[26]  T. Kodama,et al.  The Keap1/Nrf2 Protein Axis Plays a Role in Osteoclast Differentiation by Regulating Intracellular Reactive Oxygen Species Signaling* , 2013, The Journal of Biological Chemistry.

[27]  Nong Zhang,et al.  Nrf2 Pathway Regulates Multidrug-Resistance-Associated Protein 1 in Small Cell Lung Cancer , 2013, PloS one.

[28]  S. Niture,et al.  Nrf2 Protein Up-regulates Antiapoptotic Protein Bcl-2 and Prevents Cellular Apoptosis* , 2012, The Journal of Biological Chemistry.

[29]  G. Dellaire,et al.  Leukaemia xenotransplantation in zebrafish – chemotherapy response assay in vivo , 2011, British journal of haematology.

[30]  B. Zhivotovsky,et al.  Transcription factor GABP/NRF-2 controlling biogenesis of mitochondria regulates basal expression of peroxiredoxin V but the mitochondrial function of peroxiredoxin V is dispensable in the dog. , 2011, Biochimie.

[31]  V. Raman,et al.  Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. , 2010, Carcinogenesis.

[32]  Stephen G Swisher,et al.  Nrf2 and Keap1 Abnormalities in Non–Small Cell Lung Carcinoma and Association with Clinicopathologic Features , 2010, Clinical Cancer Research.

[33]  C. Winterbourn,et al.  Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. , 2010, The Biochemical journal.

[34]  B. Kalyanaraman,et al.  "ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis"--a critical commentary. , 2008, Free radical biology & medicine.

[35]  S. Goodman,et al.  RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. , 2008, Cancer research.

[36]  B. Knoops,et al.  Silencing of peroxiredoxin 3 and peroxiredoxin 5 reveals the role of mitochondrial peroxiredoxins in the protection of human neuroblastoma SH-SY5Y cells toward MPP+ , 2008, Neuroscience Letters.

[37]  P. Avila,et al.  Peroxiredoxin V Contributes to Antioxidant Defense of Lung Epithelial Cells , 2008, Lung.

[38]  B. Zhivotovsky,et al.  Mitochondrial targeting of human peroxiredoxin V protein and regulation of PRDX5 gene expression by nuclear transcription factors controlling biogenesis of mitochondria , 2007, The FEBS journal.

[39]  M. Lilly,et al.  PIM1 kinase protects cells from death induced by oxidative stress: Potential role of PRDX5 phosphorylation , 2007 .

[40]  Shyam Biswal,et al.  Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. , 2007, Annual review of pharmacology and toxicology.

[41]  T. Russo,et al.  p53 Suppresses the Nrf2-dependent Transcription of Antioxidant Response Genes* , 2006, Journal of Biological Chemistry.

[42]  O. Shupliakov,et al.  Peroxiredoxin V is essential for protection against apoptosis in human lung carcinoma cells. , 2006, Experimental cell research.

[43]  Tsutomu Ohta,et al.  Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. , 2006, Molecular cell.

[44]  G. Murrell,et al.  Overexpression of antioxidant enzyme peroxiredoxin 5 protects human tendon cells against apoptosis and loss of cellular function during oxidative stress. , 2004, Biochimica et biophysica acta.

[45]  I. Copple.  The Keap1-Nrf2 cell defense pathway--a promising therapeutic target? , 2012, Advances in pharmacology.